Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
about
Cardioprotective interventions for cancer patients receiving anthracyclinesCardioprotective interventions for cancer patients receiving anthracyclinesCardiotoxicity in childhood cancer survivors: strategies for prevention and managementDexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in MiceDexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562Cancer treatment-related cardiac toxicity: prevention, assessment and management.The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.Cardiotoxicity of cancer therapy.Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer PatientsDexrazoxane for the treatment of chemotherapy-related side effects.Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.Cardiovascular toxicities from systemic breast cancer therapy.Anthracycline cardiotoxicity: prevalence, pathogenesis and treatmentDexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.Cardiotoxic effects of anthracycline-taxane combinations.Dexrazoxane abrogates acute doxorubicin toxicity in marmoset ovaryDexrazoxane as a cardioprotectant in children receiving anthracyclinesCardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.Quantifying Drug-Induced Nanomechanics and Mechanical Effects to Single Cardiomyocytes for Optimal Drug Administration To Minimize Cardiotoxicity.Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancerOxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Anthracycline cardiotoxicity.Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.Senior adult oncology.Doxorubicin induced heart failure: Phenotype and molecular mechanisms.A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of CardiologyAqueous fish extract increases survival in the mouse model of cytostatic toxicity.Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicityChemotherapy-induced cardiomyopathy.Prevention of Chemotherapy Induced Cardiomyopathy.The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.The influence of chemotherapy on the right ventricle: did we forget something?Chemotherapy-induced cardiotoxicity in children.Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.Preventing the cardiotoxicity of anthracyclines by dexrazoxaneLiposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.Novel strategies to prevent the development of multidrug resistance (MDR) in cancer.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
P2860
Q24236338-7EFB6E50-8B2F-438A-9489-158D6C560563Q24243021-13D9441C-D378-41DF-A6EB-943DB22FFBC2Q24628695-AAC39559-A57E-44F7-88CB-F5BE7B812A3BQ27345163-6911058F-A17A-4EB4-9B28-4FE9AE2E5038Q28361976-EB48D0BF-03E5-4DBE-8A08-779464ABDF3BQ30276456-4A165E32-DE7B-4FBD-A7F6-90DEEFCC52F2Q33595716-7D29E9CF-83A0-4970-87B5-EF79B6C36E74Q33704056-0F8C1F6D-A296-4E46-9707-1297D5034C7DQ33816471-CF4B65A8-6DCA-4E08-BCD7-943A246C1AC1Q34211957-C3515FC8-5F21-4541-94BD-61BBB4674454Q34565455-56D64F16-B10D-4052-996E-612F38802190Q34630349-AED781B6-BCAD-4995-8A28-F9A9E8EA378BQ34639876-FC37C9B7-B28B-4ED6-BDD4-15999DDE3A5EQ35044266-78AB9109-AA02-426E-8A49-C70563090D9DQ35194442-9B5A025E-A0B0-4837-86F0-92B6A100FB53Q35201332-8E690726-7602-4C08-B6AA-A5D2ECA05334Q35583768-8D6DC971-AB24-4D27-8733-6DB4FE99FF94Q35849444-61EDDF80-9A5C-4333-BF03-10DEF7770D9BQ35887269-06F9484E-3546-4885-A672-EBB4744F7746Q36410651-6B3BAFE5-0719-46CB-AE73-C076FC0AA378Q36568908-EE36E73B-3A49-4488-A96D-0B09F69FAEF2Q36624983-1E6BF87B-1967-4D1C-BF8F-EB172984FA05Q36653789-741313CB-DB4F-4EBE-A208-BF311FFC31E4Q36828128-2226FC48-8ECE-4FD8-9DFD-789456014A5FQ36851424-DA9BA90C-A7EB-4602-9495-E8C2259BB2C8Q36912561-2B29ED74-6689-492E-806F-DD7DF8CF782DQ37052852-8FDBAB6E-DD9B-454F-8394-6805A6BC5FFAQ37081203-1AAD48AA-107E-4C8F-9F74-E7D71997D675Q37230118-2C4B85C8-F1E5-4C92-98D2-62F4D7D7E623Q38580452-8AD56723-B62F-47C2-903A-9F7BD1D792A9Q38639587-253F5FDD-ECFE-4A80-9494-715E0B41C6FEQ38927458-92E0E05D-88AB-4718-8FFD-76642012DD5CQ39133246-FDFCDB63-2BB5-476E-B17B-0CE8DC5B0BCAQ39415815-AE651E74-244B-401A-8F30-86CD7FA57E1BQ42537936-D27617C4-A9E4-4672-8925-7D4CB29BA1BEQ42764756-8E4F16C9-4777-47EF-8C01-E594D8C3724BQ43869754-045CCA92-D6D4-4B7D-9D5A-88330BF7396CQ46269647-EAD1B9C7-DBB2-4D07-969C-92C1896D2B92Q47129596-BD18952F-825E-4D59-A2F8-BC01343B340DQ57057499-A0709151-21ED-4FB3-B157-8E9D8D962C82
P2860
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
description
1997 nî lūn-bûn
@nan
1997 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Delayed administration of dexr ...... oxorubicin-containing therapy.
@ast
Delayed administration of dexr ...... oxorubicin-containing therapy.
@en
Delayed administration of dexr ...... oxorubicin-containing therapy.
@nl
type
label
Delayed administration of dexr ...... oxorubicin-containing therapy.
@ast
Delayed administration of dexr ...... oxorubicin-containing therapy.
@en
Delayed administration of dexr ...... oxorubicin-containing therapy.
@nl
prefLabel
Delayed administration of dexr ...... oxorubicin-containing therapy.
@ast
Delayed administration of dexr ...... oxorubicin-containing therapy.
@en
Delayed administration of dexr ...... oxorubicin-containing therapy.
@nl
P2093
P1476
Delayed administration of dexr ...... oxorubicin-containing therapy.
@en
P2093
P304
P356
10.1200/JCO.1997.15.4.1333
P407
P577
1997-04-01T00:00:00Z